Chan Hilda W, Russell Andrea M, Smith Meredith Y
Global Patient Safety and Labeling, Amgen, Inc., Thousand Oaks, CA, USA.
Health Literacy and Learning Program, Division of General Internal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):969-978. doi: 10.1002/pds.4614. Epub 2018 Jul 13.
Poor-quality patient drug information has been identified as a major cause of preventable medication errors in the United States. The US Food and Drug Administration (FDA) has the authority to require marketing authorization holders of medicinal products to implement risk evaluation and mitigation strategies (REMS) to ensure that the benefits of a drug or biological product outweigh its risks. Aside from medication guides, no research has been conducted to assess the quality of patient-targeted REMS materials, including whether, and to what extent, patients find these materials understandable and actionable.
To describe the readability, understandability, and actionability of patient educational materials in currently approved REMS programs, and to highlight opportunities for improving both the quality and effectiveness of these important drug safety tools.
Seventy-seven REMS programs were identified from the FDA REMS database. We excluded medication guides (MGs) from our analysis because of the fact that there is a mandatory MG template. Based on this, we identified a total of 27 (non-MG) REMS patient materials on the FDA REMS website for analysis purposes. The materials were tested for readability using the Lexile Measure, the Gunning Fog Index, and Flesch Kincaid and then assessed using the Patient Education Materials Assessment Tool for printable materials, for understandability and actionability.
Twenty-three of 77 (30%) REMS programs used educational materials to communicate serious risks to patients, yielding a total of 27 REMS patient materials for analysis. The median readability score for these materials was at a ninth-grade reading level or higher. While most (89%) of these patient education materials met established criteria for being understandable, less than half (49%) were deemed actionable.
Currently approved REMS patient materials fell short in terms of recommended reading level, and over half did not meet recommended standards for actionability. Developers of these materials should apply plain language principles when design these materials to improve their readability and to assess both understandability and actionability in order to increase the effectiveness when distributed to patients.
在美国,低质量的患者用药信息已被确认为可预防用药错误的主要原因。美国食品药品监督管理局(FDA)有权要求药品上市许可持有人实施风险评估和缓解策略(REMS),以确保药物或生物制品的获益大于风险。除用药指南外,尚未开展研究来评估针对患者的REMS材料的质量,包括患者是否以及在何种程度上认为这些材料易于理解且可付诸行动。
描述当前获批的REMS项目中患者教育材料的可读性、可理解性和可操作性,并突出改善这些重要药物安全工具的质量和有效性的机会。
从FDA的REMS数据库中识别出77个REMS项目。由于存在强制性的用药指南模板,我们在分析中排除了用药指南(MG)。基于此,我们在FDA的REMS网站上总共识别出27份(非MG)REMS患者材料用于分析。使用Lexile Measure、冈宁雾度指数和弗莱什-金凯德方法对这些材料进行可读性测试,然后使用针对可打印材料的患者教育材料评估工具对其可理解性和可操作性进行评估。
77个(30%)REMS项目中有23个使用教育材料向患者传达严重风险,共产生27份REMS患者材料用于分析。这些材料的可读性中位数得分处于九年级阅读水平或更高。虽然这些患者教育材料中的大多数(89%)符合既定的可理解标准,但不到一半(49%)被认为是可操作的。
当前获批的REMS患者材料在推荐阅读水平方面存在不足,超过一半不符合推荐的可操作性标准。这些材料的开发者在设计这些材料时应应用通俗易懂的语言原则,以提高其可读性,并评估可理解性和可操作性,以便在分发给患者时提高有效性。